June 14, 2022
An early-stage advisory and investment fund supporting emerging technologies in the biotech and pharmaceutical sector, today announced its participation in seed-round capital funding of Unravel Biosciences, Inc. ("Unravel"). The financial terms of the transaction were not disclosed.
Click to read the full articleJune 14, 2022
Scilex Holding Company has entered into a license and commercialization agreement with ROMEG Therapeutics for the exclusive right to market and distribute Gloperba, an oral solution for adults suffering from gout, in the US
Click to read the full articleJuly 5, 2022
Unravel Biosciences today announced a partnership with TMA Precision Health aimed at identifying rare Rett Syndrome patients for inclusion in Unravel's first-in-human reformulated drug trial.
Click to read the full articleRTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.